BGLC vs VLTO · rev $99.0K vs P/E 29, rev $5.50B
BioNexus Gene Lab Corp Common stock (BGLC) versus Veralto Corporation (VLTO) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
Veralto Corporation (VLTO) is a pollution & treatment controls company listed on US.
Latest reported BGLC revenue for 2026-06-30 was $99.0K. Net income was -$830.0K. BGLC currently screens at market cap $6.1M.
Latest reported VLTO revenue for 2025-12-31 was $5.50B. Net income was $940.0M. Revenue was up 6.0% from 2024-12-31 to 2025-12-31. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
BGLC currently screens at market cap $6.1M. VLTO currently screens at market cap $25.26B and trailing P/E 29.1.
Not investment advice. Open the BGLC and VLTO stock pages for the full models.
Not investment advice.